Are empagliflozin (Jardiance) and eplerenone appropriate for a patient with preserved left ventricular ejection fraction, mild left‑ventricular chamber enlargement and grade 1 diastolic dysfunction, despite lacking systolic dysfunction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Empagliflozin and Eplerenone in Heart Failure with Preserved Ejection Fraction

Yes, both empagliflozin and eplerenone are appropriate for your clinical scenario of preserved ejection fraction with mild left ventricular chamber enlargement and grade 1 diastolic dysfunction, even without systolic dysfunction. These medications are now indicated for heart failure with preserved ejection fraction (HFpEF), not just reduced ejection fraction.

Empagliflozin (Jardiance) in HFpEF

The evidence base has fundamentally shifted regarding SGLT2 inhibitors in preserved ejection fraction. The 2025 Canadian guidelines explicitly recommend empagliflozin for heart failure with nonreduced ejection fraction (LVEF >40%), starting at 10 mg daily 1. This represents a major paradigm change from older thinking that these drugs only worked in reduced ejection fraction.

Key Supporting Evidence

The FDA label for Jardiance now includes HFpEF as an indication based on the EMPEROR-PRESERVED trial, which enrolled 5,988 patients with LVEF >40% 2. Empagliflozin reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 21% (HR 0.79,95% CI 0.69-0.90, p=0.0003), primarily through reducing hospitalizations 2.

Critically, this benefit extended across the entire spectrum of preserved ejection fraction:

  • The drug worked in patients with LVEF 50-64% 3, 4
  • Benefits were consistent regardless of diabetes status 5
  • The effect was maintained even in patients with LVEF as high as 65%, though somewhat attenuated above that threshold 4

Mechanism in Diastolic Dysfunction

Your specific concern about diastolic dysfunction is directly addressed by mechanistic research. Empagliflozin improves diastolic function through multiple pathways 6:

  • Reduces interstitial myocardial fibrosis
  • Improves cardiomyocyte relaxation by enhancing titin phosphorylation
  • Activates the nitric oxide-cGMP-PKG signaling pathway
  • Enhances autophagy via the AMPK/mTORC1 pathway 7

These mechanisms directly target the pathophysiology of diastolic dysfunction, not just systolic function.

Eplerenone in Your Clinical Context

The evidence for eplerenone in preserved ejection fraction is more nuanced but still supportive. The 2025 Canadian guidelines recommend mineralocorticoid receptor antagonists (including eplerenone 25-50 mg daily) for HFnrEF 1.

Important Caveats for Eplerenone

The FDA label for eplerenone is based primarily on the EPHESUS trial, which studied patients post-myocardial infarction with LVEF ≤40% 8. However, the guideline recommendation extends to preserved ejection fraction based on:

  • Mechanistic benefits in reducing fibrosis and cardiac remodeling
  • The 2024 European Heart Journal systematic review of HFpEF guidelines supporting MRA use 9
  • Extrapolation from the broader heart failure literature

Key monitoring requirement: You must closely monitor potassium and renal function, as eplerenone increases hyperkalemia risk, especially when combined with ACE inhibitors or ARBs 8. Avoid if baseline potassium >5.0 mEq/L or creatinine >2.5 mg/dL 8.

Clinical Algorithm for Your Situation

For mild LV chamber enlargement with grade 1 diastolic dysfunction and preserved EF:

  1. Start empagliflozin 10 mg daily first - This has the strongest evidence in your exact clinical scenario 1, 2

    • No titration needed; 10 mg is the therapeutic dose
    • Monitor for genital infections, volume depletion
    • Benefits appear within weeks
  2. Add eplerenone 25 mg daily if:

    • You have hypertension requiring additional control
    • There are signs of neurohormonal activation (elevated natriuretic peptides)
    • Potassium <5.0 mEq/L and creatinine <2.5 mg/dL
    • Titrate to 50 mg daily after 4 weeks if tolerated 1
  3. Monitor closely:

    • Potassium and creatinine at 1 week, then monthly for first 3 months
    • Blood pressure (both drugs lower BP)
    • Symptoms of volume depletion

Common Pitfalls to Avoid

  • Don't wait for symptoms to worsen: The evidence shows benefit even in early/mild disease 1, 2
  • Don't assume these are "diabetes drugs": Benefits are independent of diabetes status 5
  • Don't combine eplerenone with potassium-sparing diuretics or potassium supplements without very close monitoring
  • Don't use empagliflozin if eGFR <20 mL/min/1.73m² (though it works well in chronic kidney disease above this threshold) 2

The 2024 European systematic review emphasizes that SGLT2 inhibitors represent the first disease-modifying therapy for HFpEF 9, fundamentally changing how we approach preserved ejection fraction. Your clinical scenario—mild diastolic dysfunction with preserved EF—is precisely the population that benefits from these medications.

Related Questions

Why was empagliflozin (Jardiance) prescribed to a patient without overt heart failure with preserved ejection fraction but with left‑ventricular concentric hypertrophy and grade 1 diastolic dysfunction, and what are its therapeutic actions?
What is the recommended empagliflozin (Jardiance) dose for patients with heart failure with preserved ejection fraction?
Can I start empagliflozin (Jardiance) 10 mg daily for my heart failure with preserved ejection fraction and iron‑deficiency anemia, given my eGFR is ≥20 mL/min/1.73 m² and I am already on diuretics, an ACE‑inhibitor/ARB/ARNI, and a mineralocorticoid‑receptor antagonist?
What are the benefits of initiating empagliflozin (10 mg) once daily in a patient with chronic heart failure (reduced or preserved ejection fraction) who does not have type 1 diabetes, active ketoacidosis, or an eGFR < 30 mL/min/1.73 m²?
How does Jardiance (empagliflozin) benefit patients with heart failure with preserved ejection fraction?
Can ziprasidone (Geodon) be taken once nightly instead of twice daily?
How should atrial fibrillation with rapid ventricular response and evidence of volume overload be managed?
What is the appropriate dose of valacyclovir (Valtrex) for treating herpes gingivostomatitis in an otherwise healthy adult?
What are the typical dispensing options for hydrocortisone 2.5% cream?
What is the recommended duration of treatment for a tubo‑ovarian abscess?
How do you vent a percutaneous endoscopic gastrostomy (PEG) tube?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.